AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01286389 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: caloric restriction
Description: Nutritional guidance: through at least 2 individual assistance and group sessions, lasting 1 hour, weekly for 4 months, and biweekly for 2 months and monthly thereafter (26-28 meetings/1year).The diet plan will recommend a deficit from 500 to 750 kcal/day in order to promote loss of about 0.5kg/week, containing 1g/kg of protein per day (minimum 1200kcal/day), high in fiber, vegetables and whole foods. The goal of weight loss will be 10% of initial weight. Group activities consist of lectures on nutrition education, food composition and its importance to health, food preparation techniques, self-monitoring weight, eating behavior and count calories.
Study NCT04686656 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: nasal oxygen
Description: Nasal cannula will be placed by the anesthesiologist. 6 l/ min of supplemental oxygen will be administered with nasal cannula.
Study NCT04686656 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: buccal oxygen
Description: Ring-adair-elwyn (RAE) tube will be placed by the anesthesiologist. 6 l/ min of supplemental oxygen will be administered with RAE tube.
Study NCT02766426 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Lifestyle change program
Description: Women attended a multidisciplinary counseling (by both the dietitian and the gynecologist). They were given nutritional advice about lifestyle and physical activity, in agreement with the Italian Guidelines for a healthy diet during pregnancy. The diet given comprised 1500 kcal/day and consisted of 3 main meals and 3 snacks (breakfast, snack, lunch, snack, dinner, and evening snack) that corresponds to the baseline metabolism of a pregnant woman. In view of the physical activity program, the dietitian added an amount of 200 kcal/day for obese or 300 kcal/day for overweight women.~The exercise intervention was focused on increasing walking and developing a more active lifestyle. The recommendation for physical activity was to perform 30 min of moderate intensity activity at least 3 days a week.
Study NCT03465917 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Renal Denervation
Description: Bilateral denervation of the renal arteries using extravascular administration of neurolytic alcohol
Study NCT02758990 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Axon Eyewear
Description: Subjects will be asked to utilize the therapeutic eyewear when exposed to bright or fluorescent light.
Study NCT01657370 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rescue medication
Description: If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours,~Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs \[NSAIDs\]), anti-emetics, triptans, opiates or other medication not explicitly excluded.
Study NCT03092310 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Pancreas Device
Description: Artificial Pancreas Device
Study NCT02758990 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chocolate
Description: Subjects will be asked to increase chocolate intake by eating 57g per day.
Study NCT01146665 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computer-based PAF
Description: This intervention includes standard medical care followed by receipt of computer-based Personalized Assessment Feedback (PAF). PAF is a type of brief intervention that targets norm misperceptions, for example summarizing a person's drinking in comparison to the average male or female in the general population. Theoretically, such normative feedback corrects norm misperceptions and motivates drinkers to re-evaluate their consumption patterns.
Study NCT01146665 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Computer-based Sham
Description: This intervention includes standard medical care followed by receipt of a computer-based sham. The sham is similar in format and duration as the computer-based Personalized Assessment Feedback but will engage youth in nutrition and exercise-related questions.
Study NCT02527005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulphadoxine-pyrimethamine
Description: Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets monthly for 3 doses
Study NCT02527005 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: Tabs Azithromycin 500mg daily for 3 days
Study NCT02013609 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brexpiprazole
Description: Treatment 12 weeks) - Up to 3 mg/day, once daily dose, tablets, orally
Study NCT01135225 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PROMUS(TM) Element (TM) Stent System
Description: The PROMUS Element Everolimus-Eluting Coronary Stent System is a device/drug combination product composed of two components: a device (coronary stent system) and a drug product (a formulation of everolimus contained in a polymer coating.
Study NCT00880997 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxazosin
Description: Medication induction occurred at a rate of 2mg/week until 8mg/day target dose was achieved as follows:~1. Dox-Fast Group: Defined as participants reaching the target dose after a 4-week titration period. Participants were stabilized on doxazosin or placebo over weeks 4-13 (for Dox-Fast group)~2. Dox-Slow Group: Defined as participants reaching the target dose after an 8-week titration period. Participants were stabilized on doxazosin or placebo over weeks 8-13 (for Dox-Slow group)~Both doxazosin groups will be tapered off doxazosin or placebo over study weeks 14-17.
Study NCT00880997 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be administered a sugar pill to mimic the doxazosin active medication with administration being the same as the active medication.
Study NCT05494931 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: corneal neurotomy
Description: Classic Gunderson conjunctival flap surgery adjuncted by corneal neurotomy
Study NCT04051528 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: aerobic exercise training
Description: The aerobic exercise will first perform 3 minutes of warm-up followed by 25 minutes of resistive aerobic exercise and then 2 minutes cool-down. During the aerobic exercise the target heart rate will be 40 to 70% of maximal heart rate calculated as (208 - 0.7 age). The exercise intensity will be progressed as the participants improve their performance throughout practice. Vital signs and the Borg Perceived Exertion Scale will be monitored and recorded during exercise for each session.
Study NCT04051528 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computerized cognitive training
Description: The core function of cognitive training will be including attention, recognition, color and shape identification, calculation, visual perception, visuospatial processing and executive function. Participants will perform tasks designed to enhance abovementioned types of cognitive functions. The difficult level of this training program will be adjusted automatically and continuously based on each participant's level of performance. Cognitive training group will use commercialized cognitive based training programs to facilitate several cognitive functions. The core function will be including attention, recognition, color and shape identification, calculation, visual perception, visuospatial processing and executive function. Participants will perform tasks designed to enhance abovementioned types of cognitive functions. The difficult level of this training program will be adjusted automatically and continuously based on each participant's level of performance.
Study NCT00522951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Description: Gadobutrol enhanced MRI (first injection of gadobutrol 0.1 mmol/kg bw, corresponding to a dose of 0.1 mmol/kg bw)
Study NCT01135225 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Evolution Stent System
Description: The Evolution Everolimus-Eluting Monorail Coronary Stent System is a device/drug combination comprised of two regulated components: a device (coronary stent stent) and a drug product (a formulation of everolimus contained in a biodegradable polymer coating).
Study NCT03816787 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Negative pressure therapy
Description: Participants assigned to the treatment group will receive wet-cupping therapy 1 times per week for 4 weeks
Study NCT03816787 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Negative pressure therapy
Description: Participants assigned to the treatment group will receive wet-cupping therapy 1 times per week for 4 weeks
Study NCT02159261 — intervention group
Intervention type: DRUG
Intervention: BAY98-7071_EE20/DRSP/L-5-MTHF
Description: Patients treated by Physicians under approved local prescriptions
Study NCT03495817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-50002
Description: ATI-50002 Topical Solution
Study NCT00635115 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: a new generation of corrective lens for presbyopia (i.e., Varilux Panamic Orma Crizal)
Study NCT00635115 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: an old generation of corrective lens for presbyopia (i.e., Varilux Comfort Orma Crizal)
Study NCT01543659 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 89Zr-DFO-huJ591
Description: The first 10 patients enrolled in the study will undergo serial whole-body scans to allow assessment of 89Zr-DFO-huJ591 biodistribution. There will be no intervening changes in therapy between the scans. The first 10 patients enrolled will also have serial blood samples drawn for PK analysis (2 -3 mL per time point). The remaining 90 patients enrolled (Patients 11-100) will have only 1 whole-body scan, at a time point to be determined based on the results for the first 10 patients. Biopsies are not mandatory, but highly recommended for the scientific purposes of the study. If feasible and the patient consents, all patients will undergo either or both of the following: (a) core biopsy of soft tissue site of disease; (b) core biopsy of bony site of disease. These biopsies will be performed following the last whole-body scan, prior to initiation of a new intervening therapy, and no more than 4 weeks after 89Zr-DFO-huJ591 administration.
Study NCT03453021 — intervention group
Intervention type: DRUG
Intervention: Mepolizumab
Study NCT04321616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine will be given orally (in the ICU in gastrointestinal tubes) with 800 mg x 2 loading dose followed by 400 mg x 2 every day for a total of 10 days.
Study NCT04321616 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remdesivir
Description: Remdesivir will be given intravenously 100 mg daily for the duration of the hospitalization and up to 10 days total course. A loading dose of 200 mg at inclusion will be given.
Study NCT04321616 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: (Standard of Care) SoC
Description: The standard of care will be supplied to all patients not receiving a drug intervention.
Study NCT02626169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: Clopidogrel 75 mg once a day by mouth for 30 days
Study NCT02626169 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor 90 mg twice daily by mouth for 30 days
Study NCT03983447 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School-based intervention to promote PA and reduce ST
Description: This intervention was realized with all the children (1st grade-5th grade) and involved :~1. Physical (Environmental) adaptation of playgrounds~2. Time adaptation of lunch breaks~3. Curriculum-based program for children~4. Workshops and newsletters for parents~5. Meetings for teachers
Study NCT00775268 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Biopsy taken
Study NCT00522951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Description: Gadobutrol enhanced MRI (second injection of gadobutrol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw)
Study NCT00522951 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ProHance
Description: ProHance enhanced MRI (two injections of gadoteridol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw)
Study NCT03696706 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: LED photobiomodulation
Description: LED photobiomodulation will be applied at 36 points, bilaterally, in the temporomandibular joint regions, around these joints, and in the regions of the masseter muscles and anterior part of the temporal muscles, three times a week, totaling 6 treatment sessions, in 2 weeks. The LED apparatus is composed of a flexible rectangular plate (10cm/12cm), which adapts to the format of the area to be treated containing 18 red LEDs - 660 nm and 18 infrared LEDs - 850 nm, with a power of 3.5 mW by LED, 4.45 mW/cm2, radiant exposure of 5.35 J/cm2, radiated area of 14.13 cm2, and energy of 75.6 J.
Study NCT03696706 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: Placebo LED photobiomodulation
Description: In this group, the same procedures as the LED group will be made, but the device will be turned off.
Study NCT04000919 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5HTP
Description: 5HTP/carbidopa (50-200 mg 5-HTP/50 mg carbidopa)
Study NCT03532906 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TAP Block
Description: Injection of Bupivacaine 0.5% 20 ml into the thickness of the right abdominal wall and of Bupivacaine 0.5% 10 ml into the surgical wounds.
Study NCT03532906 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Control
Description: Injection of Bupivacaine 0.5% 10 ml into the surgical wounds
Study NCT01981174 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 30-gauge needle
Study NCT01981174 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 32-gauge needle
Study NCT01211405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose MDMA
Description: 30 mg MDMA administered p.o. once at start of an experimental session. Upon mutual agreement, this may be followed by a supplemental dose of 15 mg MDMA 1.5 to 2 hours later
Study NCT01211405 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Medium dose MDMA
Description: 75 mg MDMA administered p.o. once at start of an experimental session. Upon mutual agreement, this may be followed by a supplemental dose of 37.5 mg MDMA 1.5 to 2 hours later
Study NCT02667288 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A-101 Solution
Study NCT02635217 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Carbon dioxide insufflation
Description: using an automated carbon dioxide insufflator the gas will be infused on demand during the endoscopies
Study NCT02635217 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: room air insufflation
Description: using standard care room air will be infused on demand
Study NCT02635217 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EGD (Esophagogastroduodenoscopy) before Colonoscopy
Description: the order of endoscopies will be randomized as well
Study NCT02635217 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy before EGD (Esophagogastroduodenoscopy)
Study NCT03997214 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: inspiratory muscle strength training
Description: The experimental group received the intervention of inspiratory muscles training 5times/week for 6 weeks, 5days/ per cycle; the patients stayed in the semi-recumbent position, recorded the initial/first measurement of MIP. The trigger sensitivity was adjusted to 10% of the first recorded MIP at the start of training, then reducing the ventilator trigger sensitivity and training duration weekly.
Study NCT00289874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast sodium
Description: montelukast 5 mg chewable tablet once daily. Up to 3 weeks of treatment.
Study NCT00289874 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: Placebo
Description: Placebo. Up to 3 weeks of treatment
Study NCT00775268 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: fluorodeoxyglucose F 18 Positron Emission Tomography and computed tomography
Description: Imaging
Study NCT00775268 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [3'-deoxy-3'-[F-18] fluorothymidine
Description: Undergo scans
Study NCT00775268 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography
Description: Undergo scans
Study NCT00775268 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fine-needle aspiration
Description: sample collected
Study NCT04051528 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: guiding training
Description: At the first time in guiding training will focus on introducing the Goal-Plan-Do-Check strategy and identifying initial three goals by the Canadian Occupational Performance Measure. At the second time in guiding training will begin with a review of the Goal-Plan-Do-Check and will apply the Goal-Plan-Do-Check to the first initial goal. Participants will review this goal and plan, describe the execution of the plan (do), and evaluate the execution of the plan (check). After each execution of the plan, the participant will rate his performance using the COPM Performance Scale, producing iterative scores for each activity. The remaining session of guiding sessions will repeat this process, review performance of identified activities, and applying the Goal-Plan-Do-Check strategy to improve performance.
Study NCT00365508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine lozenge
Description: nicotine lozenge
Study NCT03109405 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stimulation-assisted venous access
Description: Stimulation-assisted venous access
Study NCT03109405 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: 20 guage cannula for IV, tourniquet optional
Description: Standard IV cannulation using 20 ga needle, and use of tourniquet at discretion of nurse performing IV cannulation
Study NCT03109405 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 20 guage cannula for IV, tourniquet optional
Description: Standard IV cannulation using 20 ga needle, and use of tourniquet at discretion of nurse performing IV cannulation
Study NCT00365508 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nicotine patch
Description: transdermal nicotine patch
Study NCT02267083 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GPX-150 for Injection
Description: GPX-150 at a starting dose of 265 mg/m2 every 21 days for 16 cycles or until death, disease progression, or unacceptable toxicity. The dose of GPX-150 may be reduced by 25% if any dose reduction criteria are met. Two reductions are allowed per subject during the course of the study.
Study NCT03192098 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Savary bougie dilation
Description: Patients will be dilated with the use of the Savary bougienage device
Study NCT03192098 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Savary bougie dilation
Description: Patients will be dilated with the use of the Savary bougienage device
Study NCT03147183 — intervention group
Intervention type: DRUG
Intervention: Thymoglobulin
Description: This study will use non-probability, convenience sampling from patients kidney transplants who receive induction immunosuppressive therapy with thymoglobulin
Study NCT03413904 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transanal TME
Description: transanal approach to TME in rectal cancer
Study NCT03413904 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic TME
Description: laparoscopic approach to TME in rectal cancer
Study NCT00838708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SRD174 Cream
Description: topical SRD174 Cream
Study NCT00838708 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: vehicle cream
Description: topical vehicle cream
Study NCT04691050 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: OrthoMTA (BioMTA)
Description: Primary second molars without successors in which traditional root canal treatment with gutta-percha could not be performed was treated with OrthoMTA
Study NCT03660358 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: kinesiotape application
Description: kinesiotape application to diaphragm, chest wall and abdomen in preterm infants.
Study NCT04009538 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation program
Description: exercise program twice a week
Study NCT00472836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598
Description: Administration of CP-945,598 in subjects with normal renal function.
Study NCT00472836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CP-945,598
Description: Administration of CP-945,598 in subjects with severe renal impairment.
Study NCT01678053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Description: Botulinum toxin A is injected into the larynx in order to treat vocal fold granulomas.
Study NCT01678053 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole (proton pump inhibitor)
Description: Standard therapy of anti-reflux medications using omeprazole or equivalent PPI.